Mercator wins CE mark for micro-infusion catheters; MIT reveals solar-powered med equipment sterilization tool;

 @FierceMedDev: Special Report: Devicemakers plot paths out of CRM funk. Feature | Follow @FierceMedDev

 @MarkHFierce: Toshiba's medical equipment division is expanding in South Korea. Release | Follow @MarkHFierce

 @DamianFierce: Parexel says it's got its M&A eye on the Middle East and some small tech companies this year. Report | Follow @DamianFierce

> A group at the Massachusetts Institute of Technology designed a device that uses only sunlight to sterilize surgical tools or other medical equipment. Blog

> Life Technologies ($LIFE) will work with Harvard University to develop diagnostic assays that rapidly evaluate human pluripotent stem cells for use in drug discovery and research. Release

> Startup Thalmic Labs has developed an armband device that uses electromyography to read electrical activity in the muscles and then translate that data into commands for computers by way of a Bluetooth low energy connection. Story

> California's Mercator MedSystems won a CE mark for its Cricket and Bullfrog micro-infusion catheters, which are designed to deliver drug treatments across any peripheral or coronary blood vessel. Release

> The MBC health program "Green Apples" recently highlighted Stretta, Mederi Therapeutics' radio frequency device designed to treat gastroesophageal reflux disease. Release

> With Genentech reporting a shortage of Cathflo Activase, which is designed to reduce catheter occlusions, ICU Medical ($ICUI) sees an opportunity, touting its Netron needle-free catheter patency device as a worthy replacement for the back-ordered Activase. More

Biotech News

 @FierceBiotech: Popular this weekend: Celgene's blockbuster dreams fade as apremilast PhIII fails to excite. Story | Follow @FierceBiotech

@JohnCFierce: Doctors declare "functional cure" of an infant infected with HIV--A first for an infant. More | Follow @JohnCFierce

@RyanMFierce: J&J backs startup effort tackling Big Data-driven disease models. More from | Follow @RyanMFierce

> Merck KGaA fashions its 6th biotech from Serono R&D wreckage. News

> Elan woos investors with a special dividend plan for Tysabri. Item

> Novartis CEO Jimenez focuses R&D on the new blockbuster paradigm. Report

> Celgene's blockbuster dreams fade as apremalist PhIII fails to excite. Story

Pharma News

@FiercePharma: Merck CEO's biggest accomplishment so far? Standing firm on R&D spending as $MRK got pounded, he tells AP: Report | Follow @FiercePharma

@EricPFierce: Happy anniversary, Bayer. A year after India granted first compulsory license for Nexavar, board rejects appeal. News | Follow @EricPFierce

> Pfizer settles 2,000-plus Chantix suits, takes $273M charge. News

> Bristol-Myers might just make a big deal, WSJ says. More

CRO News

> Trial sites say Biogen, Forest, Bayer are top sponsors. Item

> Covance allies with M2Gen for personalized medicine, cancer trials. News

> Particle Sciences teams with Chinese CRO on solubility. More

> Capsugel bets on drug delivery with Encap buy. Report

> Synteract goes global with Harrison buyout. Article

Biotech IT News

> Could playing mobile phone games help advance cancer cures? More

> GSK jumps new IT hurdles in 'real-world' test of blockbuster hopeful. Editor's Corner

> Accelrys marks Q4 growth as buyouts weigh on bottom line. Report

> Biocon chief prescribes new tech, analytics to treat R&D woes in pharma. Story

> What Facebook and Google billionaires could do for overlooked biotech brains. Item